FIIs and DIIs are piling into these four pharma stocks. Should you follow?

While rising institutional stakes highlight growing smart-money confidence in pharma, retail investors must weigh valuations, growth drivers, and regulatory risks before deciding whether to follow suit.

This is a Mint Premium article gifted to you.
Subscribe to enjoy similar stories.

Institutional investors are piling into pharmaceutical stocks, offering clear signals on where smart money is heading. Rising buying activity from domestic and foreign funds reflects growing confidence in the sector's earnings trajectory, pipeline launches, and long-term expansion.

About the Author

Equitymaster is India's leading independent equity research platform, providing in-depth research and analysis on BSE- and NSE-listed companies since 1996. As a SEBI-registered Research Analyst [Registration No. INH000021128], Equitymaster covers the full spectrum of Indian equities — bluechip stocks, midcap stocks, smallcap stocks, and microcap stocks.<br><br> At the heart of Equitymaster's research philosophy are the principles of value investing — particularly the margin of safety and the primacy of investment over speculation.

All research is produced by an independent team of SEBI-registered research analysts with vast experience in Indian financial markets, using detailed systems and processes developed entirely in-house.<br><br> With over 17 lakh readers across 72 countries, Equitymaster is one of India's leading equity research publications. Since 1996, the goal has remained the same — to deliver honest, unbiased, and credible equity research that helps Indian investors make better, more informed decisions.

Catch all the Business News , Market News , Breaking News Events, JIO IPO Listing Today LIVE and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Topics